Department of Neurosurgery, Taichung Veterans General Hospital, Taichung, Taiwan, Republic of China.
J Neurosurg. 2010 Dec;113 Suppl:191-8. doi: 10.3171/2010.8.GKS10879.
Gamma Knife surgery (GKS) is an important part of the neurosurgical armamentarium for treatment of patients with trigeminal neuralgia (TN) and is regarded as the first-line treatment in patients with TN who have serious medical comorbidities. In this study, the authors investigated the efficacy of GKS on TN in patients with serious medical comorbidities.
Between May 2004 and September 2007, 52 severely ill patients who also had TN with Barrow Neurological Institute (BNI) facial pain scores of IV or V were entered into this study. The patients' medical records and imaging findings were reviewed by an anesthesiologist and neurosurgeons to determine whether GKS was a reasonable approach to palliate the patient's pain. All patients underwent GKS, in which a maximum dose of 80 Gy was targeted to the trigeminal nerve with or without plugging to keep the dose received by the brainstem at less than 16 Gy. After treatment, every patient had clinical follow-up every 1-3 months and filled out questionnaires designed to assess BNI facial pain and numbness scores, visual analog scale scores, and 36-Item Short Form Health Survey (SF-36) scores every 3 months until the end of the study. Statistical analysis was performed to find favorable prognostic factors related to pain relief and changes in quality of life.
The median age of the patients was 71 years, and the male/female ratio was 30:22. The median follow-up period was 54 months (at least 2 years). All patients had a positive initial response to GKS, with BNI facial pain scores at least 1 point less than respective pre-GKS scores. Three patients (5.7%) obtained BNI facial pain Score I. Twenty-three patients (44.2%) experienced pain recurrence at a median follow-up of 33 months. One patient suffered from angina and required time in an intensive care unit; another patient had bleeding from a pin wound that required suturing. Alterations in BNI scores were highly correlated to visual analog scale scores (R(2) = 0.978). In both univariate and multivariate analyses, a decreased BNI facial pain score at different time points was significantly (p < 0.05) related to younger patient age, no previous treatment, evidence of vessel compression on MR imaging, time of first GKS ≤ 24 months, physical function (SF-36), role limitation due to a physical problem (SF-36), role limitation due to an emotional problem (SF-36), mental health (SF-36), social functioning (SF-36), bodily pain (SF-36), and general health (SF-36), but was not related to vitality (SF-36). Five patients (9.6%) experienced facial numbness at a mean of 13.2 ± 3.1 months after GKS (4 patients with BNI facial numbness Score II and 1 with BNI facial numbness Score III). Post-GKS MR imaging changes, including focal contrast enhancement or T2-weighted signal alterations, were identified in 3 patients (5.7%).
Gamma Knife surgery produced significant pain relief in severely ill patients who had TN without causing appreciable morbidity. The effect of reduced pain significantly paralleled an improvement in SF-36 quality-of-life indices.
伽玛刀手术(GKS)是治疗三叉神经痛(TN)患者的神经外科武器库的重要组成部分,被认为是患有严重合并症的 TN 患者的一线治疗方法。在这项研究中,作者研究了 GKS 对患有严重合并症的 TN 患者的疗效。
2004 年 5 月至 2007 年 9 月,52 名患有严重疾病且同时患有巴罗神经研究所(BNI)面部疼痛评分为 IV 或 V 的 TN 患者被纳入本研究。麻醉师和神经外科医生对患者的病历和影像学发现进行了回顾,以确定 GKS 是否是缓解患者疼痛的合理方法。所有患者均接受 GKS 治疗,最大剂量 80Gy 靶向三叉神经,或使用插件将脑干接收到的剂量保持在 16Gy 以下。治疗后,每位患者每 1-3 个月进行临床随访,并每 3 个月填写一份问卷,以评估 BNI 面部疼痛和麻木评分、视觉模拟评分和 36 项简短健康调查(SF-36)评分,直至研究结束。进行统计分析以找到与疼痛缓解和生活质量变化相关的有利预后因素。
患者的中位年龄为 71 岁,男女比例为 30:22。中位随访时间为 54 个月(至少 2 年)。所有患者对 GKS 均有阳性初始反应,BNI 面部疼痛评分至少比各自的 GKS 前评分低 1 分。3 名患者(5.7%)获得 BNI 面部疼痛评分 I。23 名患者(44.2%)在中位随访 33 个月时出现疼痛复发。1 名患者出现心绞痛,需要入住重症监护病房;另一名患者因针孔伤口出血需要缝合。BNI 评分的变化与视觉模拟评分高度相关(R²=0.978)。在单变量和多变量分析中,不同时间点 BNI 面部疼痛评分的降低与患者年龄较小、无既往治疗、MR 成像上有血管压迫的证据、首次 GKS≤24 个月、生理功能(SF-36)、身体问题导致的角色限制(SF-36)、情绪问题导致的角色限制(SF-36)、心理健康(SF-36)、社会功能(SF-36)、躯体疼痛(SF-36)和总体健康(SF-36)显著相关(p<0.05),但与活力(SF-36)无关。5 名患者(9.6%)在 GKS 后平均 13.2±3.1 个月出现面部麻木(4 名患者 BNI 面部麻木评分 II,1 名患者 BNI 面部麻木评分 III)。3 名患者(5.7%)在 GKS 后发现磁共振成像变化,包括局灶性对比增强或 T2 加权信号改变。
GKS 可显著缓解患有 TN 的重病患者的疼痛,且不会引起明显的发病率。疼痛减轻的效果与 SF-36 生活质量指数的改善显著平行。